INDIANAPOLIS and SAN FRANCISCO and LONDON , Jan. 27, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), Vir Biotechnology, Inc. (NASDAQ: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) today announced a collaboration to evaluate a combination of two COVID-19 therapies in low-risk patients with

- BLAZE-1 trial met primary endpoint and key secondary endpoints with high statistical significance - Results from more than 1,000 high-risk patients were consistent with previous data - Findings from BLAZE-4 trial provide data on lower doses of bamlanivimab and etesevimab together - Media and

INDIANAPOLIS , Jan. 22, 2021 /PRNewswire/ --  Eli Lilly and Company (NYSE:LLY) today announced the successful completion of its acquisition of Prevail Therapeutics Inc. (NASDAQ: PRVL). The acquisition establishes a new modality for drug discovery and development at Lilly , extending Lilly 's

INDIANAPOLIS , Jan. 21, 2021 /PRNewswire/ -- Bamlanivimab (LY-CoV555) significantly reduced the risk of contracting symptomatic COVID-19 among residents and staff of long-term care facilities, Eli Lilly and Company (NYSE: LLY) announced. The Phase 3 BLAZE-2 COVID-19 prevention trial – conducted in